EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Plasma p‐tau217 identifies cognitively normal older adults who will develop cognitive impairment in a 10‐year window

Yara Yakoub, Fernando Gonzalez-Ortiz, Nicholas J Ashton, Christine Déry, Cherie Strikwerda-Brown, Frédéric St-Onge, Valentin Ourry, Michael Schöll, Maiya R Geddes, Simon Ducharme, Maxime Montembeault, Pedro Rosa-Neto und 7 weitere

Alzheimer's & Dementia · 2025-02 · 21 (2)

DOI: 10.1002/alz.14537 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 26.02.2025. Verfasst von Yara Yakoub und 18 weiteren Autor:innen. Beteiligte Einrichtung: Douglas Mental Health University Institute, Centre for Studies on the Prevention of Alzheimer's Disease (StoP-AD), Montreal, Quebec, Canada. Hauptthemen laut MEDLINE: tau Proteins, Cognitive Dysfunction. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alzheimer's Association, Swedish Research Council, the Stiftelsen för Gamla Tjänarinnor.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION We assessed the prognostic accuracy of plasma p‐tau217 in predicting the progression to mild cognitive impairment (MCI) in cognitively unimpaired (CU) individuals over a mean follow‐up of 5.65 years after plasma collection (range 1.01–10.47). METHODS We included 215 participants from the PREVENT−AD cohort with plasma Aβ 42/40 and p‐tau217, 159 with cerebrospinal fluid (CSF) Aβ 42/40 and p‐tau217, and 155 with 18 F‐NAV4694 and 18 F‐flortaucipir PET scans. MCI progression was determined by multidisciplinary consensus among memory experts blind to biomarker and genetic information. RESULTS Cox proportional hazard models indicated a greater progression rate in A+T+ plasma and A−T+ plasma compared to A−T− plasma individuals (HR = 7.81 [95% CI = 3.92 to 15.59] and HR = 4.25 [1.60–11.31] respectively). Similar results were found with CSF (HR = 3.63 [1.72–7.70]) and PET (HR = 9.30 [3.67–23.55]). DISCUSSION Plasma p‐tau217 is a prognostic marker for identifying individuals who will develop cognitive impairment within ten years. Highlights Elevated plasma p‐tau217 levels in CU individuals indicate future clinical progression. Adding plasma Aβ 42/40 status to p‐tau markers did not improve the prediction to MCI. All individuals with abnormal tau PET measured in a temporal meta‐ROI progressed to MCI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

tau ProteinsCognitive DysfunctionHumansMaleFemaleAgedDisease ProgressionAmyloid beta-PeptidesBiomarkersPositron-Emission TomographyPeptide FragmentsCohort StudiesAged, 80 and overPrognosis

Stichwörter der Autor:innen

CSFMCIPETamyloidplasmatau

Substanzen

tau ProteinsAmyloid beta-PeptidesBiomarkersPeptide Fragmentsamyloid beta-protein (1-42)

Autor:innen und Institutionen

  • Douglas Mental Health University Institute, Centre for Studies on the Prevention of Alzheimer's Disease (StoP-AD), Montreal, Quebec, Canada.
  • Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Centre for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway.
  • King's College London, Institute of Psychiatry, Psychology & Neuroscience, Maurice Wohl Clinical Neuroscience Institute, London, UK.
  • Banner Alzheimer's Institute, Phoenix, Arizona, USA.
  • School of Psychological Sciences, The University of Western Australia, Perth, Western Australia, Australia.

Förderung

  • Alzheimer's Association
  • Swedish Research Council
  • the Stiftelsen för Gamla Tjänarinnor
  • Sahlgrenska Academy at the University of Gothenburg
  • Västra Götaland Region R&D
  • Fondation Brain Canada
  • Biogen Canada
  • the Alzheimerfonden

Zitieren

APA

Yakoub, Y., Gonzalez-Ortiz, F., Ashton, N. J., Déry, C., Strikwerda-Brown, C., St-Onge, F., Ourry, V., Schöll, M., Geddes, M. R., Ducharme, S., Montembeault, M., Rosa-Neto, P., Soucy, J. P., Breitner, J. C. S., Zetterberg, H., Blennow, K., Poirier, J., Villeneuve, S., & PREVENT−AD Research Group (2025). Plasma p‐tau217 identifies cognitively normal older adults who will develop cognitive impairment in a 10‐year window. Alzheimer's & Dementia, 21(2). https://doi.org/10.1002/alz.14537

Vancouver

Yakoub Y, Gonzalez-Ortiz F, Ashton NJ, Déry C, Strikwerda-Brown C, St-Onge F, et al. Plasma p‐tau217 identifies cognitively normal older adults who will develop cognitive impairment in a 10‐year window. Alzheimer's & Dementia. 2025;21(2). doi:10.1002/alz.14537

BibTeX
@article{Yakoub2025,
  author = {Yakoub, Yara and Gonzalez-Ortiz, Fernando and Ashton, Nicholas J and Déry, Christine and Strikwerda-Brown, Cherie and St-Onge, Frédéric and Ourry, Valentin and Schöll, Michael and Geddes, Maiya R and Ducharme, Simon and Montembeault, Maxime and Rosa-Neto, Pedro and Soucy, Jean-Paul and Breitner, John C S and Zetterberg, Henrik and Blennow, Kaj and Poirier, Judes and Villeneuve, Sylvia and PREVENT−AD Research Group, PREVENT−AD Research Group},
  title = {Plasma p‐tau217 identifies cognitively normal older adults who will develop cognitive impairment in a 10‐year window},
  journal = {Alzheimer's & Dementia},
  year = {2025},
  volume = {21},
  number = {2},
  doi = {10.1002/alz.14537}
}
Kostenlos starten →